Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 9 drugs with upcoming expirations
Activity
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Regulatory
Xalkori — XALKORI
Application NDA202570 (NDA)
Xeljanz — XELJANZ
Application NDA203214 (NDA)
Bosulif — BOSULIF
Application NDA203341 (NDA)
Inlyta — INLYTA
Application NDA202324 (NDA)
Pristiq — DESVENLAFAXINE
Application NDA205208 (NDA)
Pristiq — KHEDEZLA
Application NDA204683 (NDA)
Pristiq — DESVENLAFAXINE
Application NDA204150 (NDA)
Pristiq — PRISTIQ
Application NDA021992 (NDA)
Pristiq — DESVENLAFAXINE
Application NDA205583 (NDA)
Tygacil — TIGECYCLINE
Application NDA205645 (NDA)
Xeljanz — XELJANZ XR
Application NDA208246 (NDA)
Vfend — VORICONAZOLE
Application NDA208562 (NDA)
Tygacil — TIGECYCLINE
Application NDA211158 (NDA)
Tygacil — TIGECYCLINE
Application NDA208744 (NDA)
Xeljanz — XELJANZ
Application NDA213082 (NDA)
Rapamune — FYARRO
Application NDA213312 (NDA)
Chantix — TYRVAYA
Application NDA213978 (NDA)
Rapamune — HYFTOR
Application NDA213478 (NDA)
Bosulif — BOSULIF
Application NDA217729 (NDA)
Xalkori — XALKORI
Application NDA217581 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)